Table 3 Treatments in the study analysis population as a function of treating physician
From: Management of osteoporosis and associated quality of life in post menopausal women
GPs N = 810 | Rheumatologists N = 317 | Gynaecologists N = 179 | p | Total N = 1306 | |
|---|---|---|---|---|---|
ON GOING TREATMENT | 526 (64.9%) | 150 (47.3%) | 70 (39.1%) | ≤ 0.001 | 746 (57.1%) |
Bisphosphonates | 412 (78.3%) | 98 (65.3%) | 33 (47.1%) | ≤ 0.001 | 543 (72.8%) |
Daily | 14 (3.5%) | 2 (2.1%) | 1 (3.2%) | NS | 17 (3.2%) |
Weekly | 227 (56.9%) | 60 (63.8%) | 18 (58.1%) | 305 (58.2%) | |
Monthly | 158 (39.6%) | 32 (34.0%) | 12 (38.7%) | 202 (38.6%) | |
SERM | 47 (8.9%) | 14 (9.3%) | 15 (21.4%) | 0.009 | 76 (10.2%) |
Strontium ranelate | 68 (12.9%) | 34 (22.7%) | 17 (24.3%) | 0.003 | 119 (16.0%) |
Other | 10 (1.9%) | 4 (2.7%) | 12 (17.1%) | ≤ 0.001 | 26 (3.5%) |
SUPPLEMENTATION | 671 (82.8%) | 269 (84.9%) | 146 (81.6%) | NS | 1086 (83.2%) |
Supplementation Type | N = 655 | N = 268 | N = 141 | N = 1064 | |
Calcium | 33 (5.0%) | 7 (2.6%) | 3 (2.1%) | 0.073 | 43 (4.0%) |
Vitamin D | 27 (4.1%) | 20 (7.5%) | 9 (6.4%) | 56 (5.3%) | |
Calcium + Vitamin D | 595 (90.8%) | 241 (89.9%) | 129 (91.5%) | 965 (90.7%) |